MASTL
Serine/threonine-protein kinase greatwall
Protein Summary
Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance. Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation. This gene encodes a microtubule-associated serine/threonine kinase. Mutations at this locus have been associated with autosomal dominant thrombocytopenia, also known as thrombocytopenia-2. Alternatively spliced transcript variants ...more
- ENST00000342386
- ENSP00000343446
- ENSG00000120539
- ENST00000375940
- ENSP00000365107
- ENST00000375946
- ENSP00000365113
- GW
- GWL
- THC2
- GW
- GWL
- THC2
- MAST-L
- GREATWALL
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
molecular function | 0.96 | ||
histone modification site profile | 0.88 | ||
virus perturbation | 0.88 | ||
transcription factor binding site profile | 0.69 | ||
tissue sample | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 127.48 (req: < 5)
Gene RIFs: 27 (req: <= 3)
Antibodies: 315 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 127.48 (req: >= 5)
Gene RIFs: 27 (req: > 3)
Antibodies: 315 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0